Business Context and Reporting Period
This Form 8-K Current Report was filed by ADVENTRX Pharmaceuticals, Inc. on June 29, 2009. The filing discloses the entry into a material definitive agreement regarding a registered direct public offering of securities. Note: The request metadata references "Savara Inc," but the filing text explicitly identifies the registrant as ADVENTRX Pharmaceuticals, Inc.
Key Financial Metrics and Transaction Details
- Securities Issued: 1,361 shares of 5% Series B Convertible Preferred Stock.
- Purchase Price: $1,000 per share of preferred stock.
- Gross Proceeds: Approximately $1.36 million (1,361 shares x $1,000).
- Net Proceeds: Approximately $1.2 million after deducting placement agent fees and estimated offering expenses.
- Conversion Terms: Convertible into 9,504,189 shares of common stock at a conversion price of $0.1432 per share.
- Dividend Rate: 5% annual dividend accruing until July 6, 2014.
- Make-Whole Provision: If converted prior to July 6, 2014, the company must pay $250 per $1,000 principal amount converted (less dividends paid).
- Escrow: 25% of gross proceeds (approx. $340,250) will be held in escrow to fund dividend and make-whole payments.
- Placement Agent Fees: 7.0% of gross proceeds (approx. $95,270) plus warrants to purchase up to 475,209 shares of common stock at $0.179 per share.
Material Changes and Covenants
The filing details significant restrictions on the company's operations for a period of 60 days following June 12, 2009, and ongoing covenants for the benefit of preferred stockholders. These include:
- Restrictions on amending the certificate of incorporation or bylaws.
- Prohibition on paying cash dividends or distributions on common stock or junior securities.
- Restrictions on repurchasing common stock or issuing additional equity securities.
- Limitations on incurring new indebtedness.
- Requirement to use reasonable best efforts to maintain the listing of common stock on specified U.S. securities exchanges.
Outlook, Risks, and Unusual Items
Transaction Status: The transaction is expected to close on July 6, 2009, subject to customary closing conditions.
Redemption Triggers: The company may become obligated to redeem the convertible preferred stock upon specific events, including:
- Material breach of contractual obligations to holders.
- Change in control of the company.
- Insolvency events.
- Delisting of the company's common stock from specified exchanges.
Automatic Conversion: The preferred stock will automatically convert to common stock upon a change in control.
Investor Verification Checklist
- Verify the closing of the transaction on or around July 6, 2009.
- Confirm the actual net proceeds received after finalizing offering expenses.
- Monitor the company's ability to maintain its stock exchange listing to avoid redemption triggers.
- Review the impact of the 5% dividend and potential make-whole payments on future cash flow.
- Assess the dilution impact of the 9.5 million shares issuable upon conversion and the 475,209 placement agent warrants.